CTSO READ THE FULL CTSO RESEARCH REPORT Regulatory Update on DrugSorb-ATR On April 25, 2025, the FDA issued a denial letter regarding CytoSorbents’ (NASDAQ:CTSO) De Novo Request for DrugSorb-ATR ...

Volatility in the economy is causing digital health companies to rethink their strategies for the remainder of 2025.

Changes to the U.S. regulatory landscape could dampen the ability to authorize new products AND enforce existing regulations.

The Social Security Administration is about to get a new commissioner, but that’s only the latest of a series of changes at ...

Nearly all those who have Medicare Advantage plans must deal with prior authorization. Now more prior authorization issues are appearing with Part D prescription drugs.